The result was announced during trading hours today, 19 July 2012. Before the earnings announcement, the stock had fallen as much as 1.72% at the day's low of Rs 1,643.30.

Meanwhile, the BSE Sensex was up 92.26 points, or 0.54%, to 17,277.27.

On BSE, 83,000 shares were traded in the counter as against an average daily volume of 15,050 shares in the past one quarter.

The stock hit a high of Rs 1,697.95 and a low of Rs 1,643.30 so far during the day. The stock had hit a 52-week high of Rs 1,818 on 20 April 2012. The stock had hit a 52-week low of Rs 1,387 on 22 August 2011.

The stock had outperformed the market over the past one month until 18 July 2012, rising 8.37% compared with the Sensex's 2.87% rise. The scrip had, however, underperformed the market in past one quarter, sliding 5.45% as against 1.19% fall in the Sensex.

The large-cap company has an equity capital of Rs 84.90 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories said its consolidated revenues got a boost from healthy growth in key markets of North America, Russia and other emerging markets in Global Generics segment.

During the quarter, the company launched 33 new generic products, filed 18 new product registrations and filed 7 drug master files (DMFs) globally.

Dr. Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Its major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.